For US Healthcare Professionals
I am a
Rheumatology Specialist
For US Healthcare Professionals
Full Prescribing Information
FOR ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
THE
MOST PRESCRIBED
IL-23i in active PsA*
*year-to-date TREMFYA® active PsA market share vs IL-23 inhibitors as of July 2023.
Give your patients the opportunity to emerge with:
Rapid joint improvement proven to last at 2 years*†‡
Rapid joint improvement at Week 24 (primary endpoint) with response as early as Week 4 and continued improvement at 2 years* (OLE NRI post hoc analysis)1-7
Extensive relief: More than just lasting skin clearance at 2 years†
Improvement in IGA 0/1 at Weeks 24 and 100, with additional data including PASI 90, enthesitis, dactylitis, HAQ-DI, and MDA1-6
Proven safety profile in psoriatic disease§
Proven safety across 4 pivotal clinical trials in moderate to severe plaque psoriasis and active PsA1
HAQ-DI=Health Assessment Questionnaire-Disability Index; IL-23i=interleukin 23 inhibitor; MDA=Minimal Disease Activity; NRI=nonresponder imputation; OLE=open-label extension.
*The same patients may not have responded at each time point.
†Year 2 represents Week 100.
‡After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results.
§Psoriatic disease is defined as moderate to severe plaque psoriasis and active PsA.
Robust|| coverage &
dedicated patient support
92% nationally preferred, first-line commercial coverage, no step edit required, including TNFi biosimilars7¶#
ONCE A PRESCRIBING DECISION HAS BEEN MADE
The information provided does not imply comparable safety or efficacy between products and only represents access information. Humira is a registered trademark of AbbVie Inc. Please refer to each product’s prescribing information for indication(s), recommend dosing, and administration.
ǁRobust = >80% of commercially covered lives.
¶These percentages may not represent 100% of formulary lives due to data limitations.
#“Preferred” means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.
Have a discussion with a Janssen representative
Talk with a Janssen representative
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126-1136. 3. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115-1125. 4. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naïve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604-616. 5. McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, a monoclonal antibody specific to the p-19 subunit of interleukin-23, through 2 years: results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis. Poster presented at: Innovations in Dermatology 2021; Virtual; March 16-20, 2021. 6. Data on file. Janssen Biotech, Inc. 7. Data provided by Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of October 2023.
